Cognoptix Begins Pre-Pivotal Clinical Trial of Its Drug/Device Test Designed to Identify Alzheimer's Disease Via Beta Amyloid Signature in the Eyes
2/28/2013 9:50:21 AM
ACTON, Mass.--(BUSINESS WIRE)--Cognoptix announced today that it has begun a 40-patient clinical trial of its SAPPHIRE II eye test designed to identify Alzheimer’s disease patients via a beta amyloid (“Ab”) signature in their eyes. By detecting a specific fluorescent signature of ligand-marked beta-amyloid in the supranucleus region of the human lens, SAPPHIRE II achieved a two-fold differentiation factor between a group of five healthy volunteers and a group of five patients diagnosed with probable Alzheimer’s disease in a recent proof-of-concept clinical trial. Cognoptix has exclusively licensed groundbreaking technology from the University of California at San Diego (“UC San Diego”), which Cognoptix has developed into an innovative, non-invasive eye-scanning test, SAPPHIRE II, for the early detection and diagnosis of Alzheimer’s disease (“AD”) pathology. The UC San Diego technology is the subject of a scientific paper recently published in the peer-reviewed Journal of the American Chemical Society (“Aminonaphthalene 2-Cyanoacrylate [ANCA] Probes Fluorescently Discriminate between Amyloid-ß and Prion Plaques in Brain”). In addition to UC San Diego, exclusive licenses have been acquired from Massachusetts General Hospital and Brigham and Women’s Hospital Boston.
comments powered by